Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jay F Sarthy

Showing results (11-20 of 24) with videos related to

Pageof 3
Sort By:
Plos Biology|April 17, 2025
The length of the G1 phase is an essential determinant of H3K27me3 landscapes across diverse cell typesAbby Trouth, Kameswaran Ravichandran, Philip R Gafken, et al.
Nature Communications|October 30, 2024
MLL oncoprotein levels influence leukemia lineage identitiesDerek H Janssens, Melodie Duran, Dominik J Otto, et al.
Biorxiv : the Preprint Server for Biology|January 18, 2024
KMT2A oncoproteins induce epigenetic resistance to targeted therapiesDerek H Janssens, Melodie Duran, Dominik J Otto, et al.
Biorxiv : the Preprint Server for Biology|December 18, 2023
G1 length dictates H3K27me3 landscapesAbby Trouth, Kamesh Ravichandran, Philip R Gafken, et al.
Elife|September 9, 2020
Histone deposition pathways determine the chromatin landscapes of H3.1 and H3.3 K27M oncohistonesJay F Sarthy, Michael P Meers, Derek H Janssens, et al.
Biorxiv : the Preprint Server for Biology|July 16, 2025
Multimodal single-cell analyses reveal distinct fusion-regulated transcriptional programs in Ewing sarcomaOlivia G Waltner, April A Apfelbaum, Emma D Wrenn, et al.
Nature Biotechnology|April 13, 2021
Single-cell CUT&Tag analysis of chromatin modifications in differentiation and tumor progressionSteven J Wu, Scott N Furlan, Anca B Mihalas, et al.
Biorxiv : the Preprint Server for Biology|September 11, 2023
Chromatin Profiling of CBFA2T3-GLIS2 AMLs Identifies Key Transcription Factor Dependencies and BRG1 Inhibition as a Novel Therapeutic StrategySamantha Kaonis, Jenny L Smith, Neerja Katiyar, et al.
Pediatric Blood & Cancer|November 27, 2025
Determining Preclinical Safety of Aclarubicin in Pediatric MalignanciesDarleen S Tu, Aaron K Olson, Kimberly S Waggie, et al.
Biorxiv : the Preprint Server for Biology|June 6, 2025
Determining preclinical safety of Aclarubicin in pediatric malignanciesDarleen S Tu, Aaron K Olson, Kimberly S Waggie, et al.
Pageof 3

Showing results (11-20 of 24) with videos related to

Sort By:
Pageof 3
Plos Biology|April 17, 2025
The length of the G1 phase is an essential determinant of H3K27me3 landscapes across diverse cell typesAbby Trouth, Kameswaran Ravichandran, Philip R Gafken, et al.
Nature Communications|October 30, 2024
MLL oncoprotein levels influence leukemia lineage identitiesDerek H Janssens, Melodie Duran, Dominik J Otto, et al.
Biorxiv : the Preprint Server for Biology|January 18, 2024
KMT2A oncoproteins induce epigenetic resistance to targeted therapiesDerek H Janssens, Melodie Duran, Dominik J Otto, et al.
Biorxiv : the Preprint Server for Biology|December 18, 2023
G1 length dictates H3K27me3 landscapesAbby Trouth, Kamesh Ravichandran, Philip R Gafken, et al.
Elife|September 9, 2020
Histone deposition pathways determine the chromatin landscapes of H3.1 and H3.3 K27M oncohistonesJay F Sarthy, Michael P Meers, Derek H Janssens, et al.
Biorxiv : the Preprint Server for Biology|July 16, 2025
Multimodal single-cell analyses reveal distinct fusion-regulated transcriptional programs in Ewing sarcomaOlivia G Waltner, April A Apfelbaum, Emma D Wrenn, et al.
Nature Biotechnology|April 13, 2021
Single-cell CUT&Tag analysis of chromatin modifications in differentiation and tumor progressionSteven J Wu, Scott N Furlan, Anca B Mihalas, et al.
Biorxiv : the Preprint Server for Biology|September 11, 2023
Chromatin Profiling of CBFA2T3-GLIS2 AMLs Identifies Key Transcription Factor Dependencies and BRG1 Inhibition as a Novel Therapeutic StrategySamantha Kaonis, Jenny L Smith, Neerja Katiyar, et al.
Pediatric Blood & Cancer|November 27, 2025
Determining Preclinical Safety of Aclarubicin in Pediatric MalignanciesDarleen S Tu, Aaron K Olson, Kimberly S Waggie, et al.
Biorxiv : the Preprint Server for Biology|June 6, 2025
Determining preclinical safety of Aclarubicin in pediatric malignanciesDarleen S Tu, Aaron K Olson, Kimberly S Waggie, et al.
Pageof 3